Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabel T Rubio

Showing results (81-90 of 118) with videos related to

Pageof 12
Sort By:
NPJ Breast Cancer|November 3, 2024
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancersFlorentine S Hilbers, Coralie Poncet, Konstantinos Tryfonidis, et al.
Journal of the National Cancer Institute|September 26, 2014
Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapyJosep Lluís Parra-Palau, Beatriz Morancho, Vicente Peg, et al.
Cancer|May 4, 2018
Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysisAntonios Valachis, Eleftherios P Mamounas, Elizabeth A Mittendorf, et al.
The British Journal of Surgery|June 29, 2022
Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST surveyMaria Luisa Gasparri, Jana de Boniface, Philip Poortmans, et al.
The British Journal of Surgery|September 18, 2025
BJS commission on the surgical management of the axilla in breast cancerMichael R Boland, Oreste D Gentilini, G Bruce Mann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 1, 2024
Joint EANM-SNMMI guidelines on the role of 2-[<sup>18</sup>F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelinesDavid Groheux, Sofia C Vaz, Gary A Ulaner, et al.
NPJ Breast Cancer|November 26, 2021
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trialTomás Pascual, Mafalda Oliveira, Patricia Villagrasa, et al.
Breast (Edinburgh, Scotland)|September 20, 2024
Role of [<sup>18</sup>F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelinesDavid Groheux, Sofia C Vaz, Philip Poortmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2025
[<sup>18</sup>F]-Labeled Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Staging and Restaging Patients With Breast CancerDavid Groheux, Sofia C Vaz, Lioe-Fee de Geus-Oei, et al.
Plos One|June 16, 2015
Patterns of HER2 Gene Amplification and Response to Anti-HER2 TherapiesRocio Vicario, Vicente Peg, Beatriz Morancho, et al.
Pageof 12

Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
NPJ Breast Cancer|November 3, 2024
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancersFlorentine S Hilbers, Coralie Poncet, Konstantinos Tryfonidis, et al.
Journal of the National Cancer Institute|September 26, 2014
Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapyJosep Lluís Parra-Palau, Beatriz Morancho, Vicente Peg, et al.
Cancer|May 4, 2018
Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysisAntonios Valachis, Eleftherios P Mamounas, Elizabeth A Mittendorf, et al.
The British Journal of Surgery|June 29, 2022
Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST surveyMaria Luisa Gasparri, Jana de Boniface, Philip Poortmans, et al.
The British Journal of Surgery|September 18, 2025
BJS commission on the surgical management of the axilla in breast cancerMichael R Boland, Oreste D Gentilini, G Bruce Mann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 1, 2024
Joint EANM-SNMMI guidelines on the role of 2-[<sup>18</sup>F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelinesDavid Groheux, Sofia C Vaz, Gary A Ulaner, et al.
NPJ Breast Cancer|November 26, 2021
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trialTomás Pascual, Mafalda Oliveira, Patricia Villagrasa, et al.
Breast (Edinburgh, Scotland)|September 20, 2024
Role of [<sup>18</sup>F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelinesDavid Groheux, Sofia C Vaz, Philip Poortmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2025
[<sup>18</sup>F]-Labeled Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Staging and Restaging Patients With Breast CancerDavid Groheux, Sofia C Vaz, Lioe-Fee de Geus-Oei, et al.
Plos One|June 16, 2015
Patterns of HER2 Gene Amplification and Response to Anti-HER2 TherapiesRocio Vicario, Vicente Peg, Beatriz Morancho, et al.
Pageof 12